Related Experiment Video
Updated: Mar 19, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients
Bonpei Takase1, Hidemi Hattori2, Yoshihiro Tanaka2
1Department of Intensive Care Medicine , National Defense Medical College , Saitama , Japan.
Background:
Pitavastatin is a statin with strong pleiotropic effects, but the effects of pitavastatin on endothelial cell function (ECF) and both inflammatory cytokines and chemokines have not been fully investigated.
Material And Methods:
We simultaneously measured brachial artery (BA) flow-mediated vasodilatation (FMD) and nitroglycerin-mediated vasodilatation (NMD), as well as plasma biomarkers of inflammatory cytokines and chemokines, in patients with hypercholesterolaemia and other atherosclerotic risk factors who were treated with pitavastatin. Sixty-five hypercholesterolaemic patients (age, 66±11 years) with conventional coronary risk factors were enrolled. BA FMD, BA NMD and serum biomarkers (tumour necrosis factor, interleukin (IL)-6, IL-10, monocyte chemoattractant protein-1, IL-8, P-selectin, E-selectin, soluble intercellular cell adhesion molecule-1 (s-ICAM1)) were measured before and after 4 weeks of treatment with pitavastatin (2 mg/day).
Results:
Pitavastatin treatment resulted in an increase from baseline to post-treatment in FMD (3.22±1.72 vs 3.97±2.18%, p<0.05) but not in NMD. Furthermore, pitavastatin treatment led to a decrease from baseline to post-treatment in E-selectin (51±27 vs 46±29 pg/mL, p<0.05) and s-ICAM1 (276±86 vs 258±91 pg/mL, p<0.05). Changes in FMD in response to pitavastatin treatment did not correlate with those of E-selectin or s-ICAM1.
Conclusions:
Pitavastatin treatment resulted in a subacute improvement in ECF and a decrease in chemokine levels. These results suggest that pitavastatin might improve long-term outcomes in patients with atherosclerotic disorders.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...